Table 2.
Lifetime attributable risks (LAR) for second solid cancer incidences assuming an 8/14-year old female/male treated with 54-Gy (Gy[RBE]) target dose (cranial lesion; field 6). For breast, instead of combining the two transport models we quote the estimates separately.
| Organs | LAR (%) |
Baseline(%) | ||
|---|---|---|---|---|
| Passive scattered proton therapy | IMRT | Proton beam scanning | ||
| Larynx | 0.08/0.14 | 0.04/0.12 | 0.02/<0.01 | 0.15/0.61 |
| Thyroid | 1.39/0.15 | 0.64/0.06 | 0.18/0.01 | 1.10/0.38 |
| Bronchi | 0.68/0.23 | 0.17/0.13 | 0.03/0.03 | 6.67/7.76 |
| Breasts EAR | 0.78/- | 0.33/- | 0.04/- | 13/- |
| Breasts ERR | 0.45/- | 0.19/- | 0.02/- | 13/- |
| Lungs | 0.39/0.14 | 0.16/0.14 | 0.04/0.02 | 6.67/7.76 |
| Esophagus | 0.04/0.07 | 0.01/0.05 | 0.01/ | 0.24/0.75 |
| Liver | 0.01/0.01 | 0.01/0.03 | <0.01/<0.01 | 0.41/0.90 |
| Pancreas | 0.04/0.01 | 0.09/0.18 | 0.01/<0.01 | 1.24/1.25 |
| Kidneys | 0.01/0.01 | 0.04/0.08 | <0.01/<0.01 | 1.02/1.69 |
| Uterus/Prostate | <0.01/<0.01 | 0.01/0.01 | <0.01/<0.01 | 2.5/16.01 |
| Ovaries/Testes | <0.01/<0.01 | 0.02/0.02 | <0.01/<0.01 | 1.42/0.37 |
| Bladder Wall | <0.01/0.01 | 0.04/0.02 | <0.01/<0.01 | 1.25/3.98 |